DMTHF-Tc (original) (raw)
DMTHF-Tc (5N,10N-dimethyl tetrahydrofolic acid) is a radiopharmaceutical which combines DMTHF, a modified folate, with technetium-99m (99mTc), a gamma emitting radionuclide, in a chelate conjugate. It shows selectivity for certain cancer cells which overexpress FR-α, and can therefore be used for diagnostic imaging in nuclear medicine. DMTHF-Tc was developed by the Philip Low lab at Purdue University.
| Property | Value |
|---|---|
| dbo:abstract | DMTHF-Tc (5N,10N-dimethyl tetrahydrofolic acid) is a radiopharmaceutical which combines DMTHF, a modified folate, with technetium-99m (99mTc), a gamma emitting radionuclide, in a chelate conjugate. It shows selectivity for certain cancer cells which overexpress FR-α, and can therefore be used for diagnostic imaging in nuclear medicine. DMTHF-Tc was developed by the Philip Low lab at Purdue University. DMTHF-Tc is a type of folate targeting, an imaging and drug delivery method where the folate receptor (FR), being upregulated on malignant and inflamed cell types, is targeted. It can be used to reduce drug toxicity, as well as to visualize or quantify the amount of disease in cancerous and inflamed tissue. In normal tissues, the FR shows limited distribution. However, in cancer cells, FR-α shows upregulation, while FR-β expression is increased in inflamed tissues on activated macrophages. Because the receptor has these two isoforms that are only 76% homologous, the isoforms can be selectively bound in different types of diseased tissue for folate targeting. (en) |
| dbo:wikiPageID | 42869400 (xsd:integer) |
| dbo:wikiPageLength | 6931 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1026647735 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Cancer dbr:Purdue_University dbr:FOLR2 dbr:List_of_contaminated_cell_lines dbc:Targeted_therapy dbr:Ulcerative_colitis dbr:Downregulation_and_upregulation dbr:Radiopharmaceutical dbr:Collagen-induced_arthritis dbr:Endocyte dbr:Conjugated_system dbr:Macrophages dbr:Folate dbr:Nuclear_medicine dbr:Overexpress dbr:Folate_receptor dbr:Folate_targeting dbr:Fluorodeoxyglucose dbr:Folate_receptor_1 dbr:Isoform dbr:Atherosclerosis dbr:Technetium-99m dbr:Technetium_(99mTc)_etarfolatide dbr:Tetrahydrofolic_acid dbr:Chelation dbr:Biodistribution dbr:Radionuclide dbr:Sequence_homology dbr:Methyl_group dbr:Immunoassay dbr:Immunofluorescence dbr:Drug_toxicity dbr:Gamma_emission dbr:Activated_macrophage dbr:Diagnostic_imaging dbr:Cardiotoxin dbr:Dimethylated |
| dbp:wikiPageUsesTemplate | dbt:Cn dbt:Orphan dbt:Reflist dbt:Technical |
| dcterms:subject | dbc:Targeted_therapy |
| gold:hypernym | dbr:Imaging |
| rdf:type | dbo:Work |
| rdfs:comment | DMTHF-Tc (5N,10N-dimethyl tetrahydrofolic acid) is a radiopharmaceutical which combines DMTHF, a modified folate, with technetium-99m (99mTc), a gamma emitting radionuclide, in a chelate conjugate. It shows selectivity for certain cancer cells which overexpress FR-α, and can therefore be used for diagnostic imaging in nuclear medicine. DMTHF-Tc was developed by the Philip Low lab at Purdue University. (en) |
| rdfs:label | DMTHF-Tc (en) |
| owl:sameAs | freebase:DMTHF-Tc wikidata:DMTHF-Tc https://global.dbpedia.org/id/n8jZ |
| prov:wasDerivedFrom | wikipedia-en:DMTHF-Tc?oldid=1026647735&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:DMTHF-Tc |
| is foaf:primaryTopic of | wikipedia-en:DMTHF-Tc |